Browse evidence-based analysis of health-related claims and assertions
Log in to see full claim details, scientific mechanisms, and cited studies.
In adults with obesity taking semaglutide for 12 months, measurable improvements were seen in blood sugar, cholesterol, blood pressure, liver enzymes, and cardiovascular risk indicators.
Among adults with obesity taking semaglutide for a year, those without type 2 diabetes lost an average of 16.9% of their body weight, while those with type 2 diabetes lost an average of 9.9%.
In adults with obesity who took weekly semaglutide for one year, most lost at least 5% of their body weight, with many losing 10% or more, and a smaller group losing 20% or more.
In one person taking tirzepatide, a specific brainwave pattern in the nucleus accumbens was not present when food-related thoughts decreased. This pattern may be linked to how strongly someone is...
In one person taking tirzepatide, a specific brainwave pattern in a region linked to reward processing appeared about seven weeks before intense food cravings returned, indicating this pattern might...
In three individuals, including one taking tirzepatide, brain wave activity in the nucleus accumbens at frequencies below 7 Hz increased during intense food-focused thoughts compared to periods...
In one person with obesity and type 2 diabetes, changes in intense food cravings were linked to changes in a specific brainwave pattern in a region involved in reward processing during treatment with...
In one person with severe obesity and type 2 diabetes taking tirzepatide, a specific pattern of brainwave activity in a region linked to reward processing occurred at the same time as intense...
In obese mice, using GLP-1 receptor agonists to lose weight does not cause more muscle loss during periods of inactivity than reducing calorie intake alone.
In obese mice undergoing weight loss, drugs that activate GLP-1 receptors cause a larger decrease in liver size compared to muscle size, suggesting these drugs primarily affect how the liver...
When people lose the same amount of weight through either GLP-1 receptor agonists or calorie restriction, the drugs cause different changes in muscle proteins related to energy production and protein...
In obese mice, GLP-1 receptor agonists help maintain muscle function during weight loss by causing more fat to be lost than muscle, so the mice can run as well as lean mice even though their muscles...
In obese individuals with type 2 diabetes and in obese mice, GLP-1 receptor agonists cause weight loss primarily from fat tissue, while muscle mass is largely preserved. This results in a higher...
In obese adults with existing heart disease but no diabetes, a weekly injection of semaglutide at 2.4 mg is associated with a lower rate of serious heart-related events such as heart attack or stroke.
In obese adults with heart disease but no diabetes, taking a weekly 2.4 mg dose of semaglutide was linked to an average treatment duration of 34.2 months and follow-up of 39.8 months in clinical...
For adults with obesity and heart disease but no diabetes, a weekly injection of semaglutide at 2.4 mg lowers the chance of serious heart problems like heart attack or stroke by 20% over about 3.3...
In obese adults without diabetes but with heart disease, weekly injections of semaglutide at 2.4 mg led to a higher rate of patients stopping treatment because of side effects compared to those...
In adults over 45 with heart disease and obesity but no diabetes, a weekly injection of semaglutide at 2.4 mg for about 3.3 years lowers the combined risk of heart-related death, heart attack, or...
In people with type 2 diabetes, the drug tirzepatide lowers proinsulin and the ratio of proinsulin to insulin more than dulaglutide, suggesting more efficient insulin production and less stress in...
In people with type 2 diabetes, tirzepatide lowers fasting glucagon levels more than dulaglutide, which may help reduce excessive glucose release from the liver and improve blood sugar control.
In people with type 2 diabetes, a medication called tirzepatide at doses of 5 mg or higher raises levels of certain blood proteins—adiponectin, IGFBP-1, and IGFBP-2—more than another medication...
In people with type 2 diabetes, the medication tirzepatide at 10 mg and 15 mg improves how the body responds to insulin more than can be explained by weight loss alone, suggesting other biological...
In people with type 2 diabetes, a weekly injection of tirzepatide at 10 mg or 15 mg is associated with better function of insulin-producing cells in the pancreas, shown by specific biomarker changes,...
In people with obesity and prediabetes, losing weight through diet improves how the liver responds to insulin, but does not improve how muscles and other tissues respond to insulin.